FDA is considering increasing user fees or lengthening the review performance goals for pre-market submissions that bundle multiple devices into a single application. According to agency staffers, the current review paradigm for bundled submissions and certain diagnostic 510(k) submissions creates an uneven playing field. A bundled submission may include multiple devices, or multiple indications for use for one device, in a single pre-market submission.
